Trial
Neurology

Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson's Disease Receiving Levodopa-based

Active recruiting

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational drug, dipraglurant (ADX48621), in subjects with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID).

 

Contact: Sara Boarman 217-545-6829
Trial
Neurology

Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

Active not recruiting

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

Contact: Rylee Manka 217-545-1394
Trial
Psychiatry

RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression

Active recruiting

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

Contact: Oladele (Dickson) Owasoyo 217-545-7231
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
Trial
Neurology

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Active recruiting

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

Contact: Stephanie Kohlrus 217-545-3013
News

Report, Webinar Focuses on Impact of COVID-19 and the Rural Health Workforce

SPRINGFIELD, IL – A new report dissects the impact of COVID-19 on the rural health workforce and identifies methods the state can utilize current health workers more efficiently while committing to long-term rural health workforce recruitment strategies. “Pre-pandemic, rural regions suffered from significant healthcare provider shortages, which often required rural residents to travel long distances or wait longer for appointments,” said Dr. Sameer Vohra, Chair, SIU Medicine Department of Population Science and Policy. “Despite rural health workers’ heroic efforts during the pandemic, job
General Results

Denim and Diamonds Annual Event

General Results

Alana Knudson, PhD

Alana Knudson, PhD, serves as a Program Area Director in the Public Health Department at NORC at the University of Chicago and is the Director of NORC’s Walsh Center for Rural Health Analysis. Dr. Knudson has over 25 years of experience implementing and directing public health programs, leading health services and policy research projects, and evaluating program effectiveness. She has led projects funded by many federal agencies and private foundations. Dr. Knudson currently serves as the Project Director for the Rural Cohort Analysis of Rural Health Programs funded by the Federal Office of
Subscribe to Research